Etoposide phosphate

磷酸依托泊苷

Report date: 2023/05/05 18:02:22
NME

Base Information

Drug NameEtoposide phosphate
Drug Alias NameEtopophosBMY-40481
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase (DNA) II alpha inhibitors
TargetsTopoisomerase (DNA) II alpha
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursNeutropenia +[36] 
Global Approved IndicationsSmall Cell Lung CarcinomaTesticular NeoplasmsMultiple Myeloma +[6] 
Approved Indications in ChinaSmall Cell Lung CarcinomaTesticular Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date1996/05/17
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesCheplapharm Arzneimittel GmbhChongqing Huapont Pharmaceutical Co Ltd
Inactive CompaniesDana-Farber Cancer InstituteNational Institutes Of Health Clinical Center (Cc)University Medical Center Groningen +[17] 
Active IndicationsSmall Cell Lung CarcinomaTesticular NeoplasmsMultiple Myeloma +[6] 
Inactive IndicationsCNS Embryonal TumorSolid tumoursNeutropenia +[30] 

Other Information

ATC CodeL01CB01
Related LinksWikipediaDrugBankKEGG